{"entity":{"id":"kln-1010","kind":"drug","name":"KLN-1010","aka":[],"tldr":"KLN-1010 is an experimental in vivo CAR-T gene therapy from Kelonia Therapeutics, in phase 1 trials for relapsed and refractory multiple myeloma.","summary":"KLN-1010 is an in vivo CAR-T gene therapy (lentiviral-based iGPS particles, one-time intravenous dose) from Kelonia Therapeutics, with Eli Lilly and Company as acquirer. A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed. Its furthest stage is phase 1, for relapsed and refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase 1 inMMyCAR open and enrolling (NCT07075185). Eli Lilly agreed to acquire Kelonia (announced 20 April 2026; up to $7.00 billion); site now says 'A wholly owned subsidiary of Eli Lilly and Company'. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Kelonia Therapeutics: keloniatx.com","url":"https://keloniatx.com/pipeline/"},{"label":"Kelonia Therapeutics: pharmalive.com","url":"https://www.pharmalive.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies/"},{"label":"Kelonia Therapeutics: keloniatx.com","url":"https://keloniatx.com/"},{"label":"Kelonia Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07075185"},{"label":"ClinicalTrials.gov: trials of KLN-1010","url":"https://clinicaltrials.gov/search?intr=KLN-1010"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":["kelonia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07075185"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"KLN-1010","modality":"In vivo CAR-T gene therapy (lentiviral-based iGPS particles, one-time intravenous dose)","mechanism":"A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/kln-1010/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/"}],"trial":[{"id":"nct07075185","kind":"trial","name":"A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","route":"/trials/nct07075185/"}]}}